# The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

> **NCT00171314** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 527 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00171314
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171314, "The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00171314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*